Skip to main content
OpenTrials
Completed

NCT Number: NCT00177580

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms of schizophrenia, and also to improve cognitive functioning.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Western Psychiatric Institute & Clinic

Pittsburgh, Pennsylvania, 15213, United States

About this study

This study supplements patients' current medications with Pravastatin, a cholesterol-lowering medication, to try to improve residual symptoms and also to improve cognitive functioning. It consists of 15 total study visits over a 28-week period of time, one visit every 2 weeks.

Blood draws will be done once every 4 weeks throughout the study to monitor lipid levels, C-Reactive protein, AST, ALT, and CPK Total. Cognitive testing will be completed at the beginning of the study and at the end of the study. During the study visits, the staff will be monitoring vitals signs (weight, height, blood pressure, pulse, waist/hip ratio), possible side effects, positive and negative symptoms, mood symptoms, and overall functioning.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of schizophrenia or schizoaffective disorder
  • Male and female subjects; age 18-65 years inclusive
  • Ability to provide informed consent
  • No psychiatric hospitalization in the last 30 days prior to randomization
  • PANSS score at study entry between 80 and 120 inclusive, OR those who continue to experience some residual positive and/or negative symptoms and are not at their baseline level of functioning.
  • Current psychiatric medications stable for at least 30 days
  • Currently receiving only one antipsychotic medication
  • Female subjects of child-bearing age must use an acceptable method of birth control

Exclusion criteria

  • Active, uncontrolled, or chronic liver disease
  • Heart failure
  • Current alcohol abuse or dependence
  • Female subjects who are pregnant, lactating or plan to become pregnant during the study period
  • History of allergic reaction with any statin in the past
  • Kidney disorder or other evidence of renal dysfunction
  • Uncontrolled diabetes
  • Untreated hyperlipidemia
  • Concurrently receiving treatment with cyclosporine, gemfibrozil, clofibrate, fenofibrate, niacin, macrolide antibiotics, erythromycin, HIV protease inhibitors, nefazodone, or verapamil

Treatment and study plan

Pravastatin

Drug

Primary outcomes

  1. PANSS total score (clinical state)

Secondary outcomes

  1. Safety

  2. Positive Symptoms

  3. Negative Symptoms

  4. Depressive Symptoms

  5. Cognitive Functions

  6. Social Functioning

  7. C-Reactive Protein changes

  8. Lipid Enzyme changes

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • Stanley Medical Research Institute

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of Adjunctive Treatment With Pravastatin in Partially Remitted Patients With Schizophrenia or Schizoaffective Disorder

Important dates

Study start
2003
Primary completion
2007
Study completion
2007
First posted
Sep 15, 2005
Registry last updated
Jan 15, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.